Connect your AI

AtriCure ATRC 2029

2029 at other companies

AbbottABT

——

Avanos MedicalAVNS

——

Other financials

Income statement

Revenue$141.2M+14.3%

Gross profit$109.3M+18.0%

Operating income$526.0K+109%

Net income$108.0K+102%

EPS (diluted)$0.00+100%

Balance sheet

Cash & equivalents$146.2M+46.3%

Total debt$76.2M-3.1%

Total equity$491.7M+8.2%

Total assets$644.0M+8.8%

Cash flow

Operating cash flow-$4.0M+63.8%

CapEx$3.9M+76.6%

Free cash flow-$7.8M+40.6%

Valuation

Market cap$1.43B-7.9%

Enterprise value$1.36B-11.2%

P/S2.6×-0.6×

Profitability

Gross margin75.6%+0.8pp

Operating margin-5.1%-1.3pp

Net margin-5.6%-1.5pp

FCF margin9.7%—

Returns & leverage

Return on equity-6.1%-1.3pp

Debt / equity0.2×0.0×

Current ratio4.3×+0.2×

Where this comes from

Reported directly by AtriCure in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree.

The official record: AtriCure’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about AtriCure's 2029.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is AtriCure's 2029?: AtriCure (ATRC) reported 2029 of $61M in Q1 2026.